Literature DB >> 18385288

Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity.

Shaukat A Khan1, Matthew S Nelson, Chendong Pan, Patrick M Gaffney, Pankaj Gupta.   

Abstract

Bone morphogenetic proteins (BMPs) and their endogenous antagonists are important for brain and bone development and tumor initiation and progression. Heparan sulfate (HS) proteoglycans (HSPG) modulate the activities of BMPs and their antagonists. How glycosaminoglycans (GAGs) influence BMP activity in various malignancies and in inherited abnormalities of GAG metabolism, and the structural features of GAGs essential for modulation of BMP signaling, remain incompletely defined. We examined whether chemically modified soluble heparins, the endogenous HS in malignant cells and the HS accumulated in Hurler syndrome cells influence BMP-4 signaling and activity. We show that both exogenous (soluble) and endogenous GAGs modulate BMP-4 signaling and activity, and that this effect is dependent on specific sulfate residues of GAGs. Our studies suggest that endogenous sulfated GAGs promote the proliferation and impair differentiation of malignant human cells, providing the rationale for investigating whether pharmacological agents that inhibit GAG synthesis or function might reverse this effect. Our demonstration of impairment of BMP-4 signaling by GAGs in multipotent stem cells in human Hurler syndrome identifies a mechanism that might contribute to the progressive neurological and skeletal abnormalities in Hurler syndrome and related mucopolysaccharidoses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385288     DOI: 10.1152/ajpcell.00346.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  21 in total

1.  Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Authors:  Shaoliang Li; Chisei Shimono; Naoko Norioka; Itsuko Nakano; Tetsuo Okubo; Yoshiko Yagi; Maria Hayashi; Yuya Sato; Hitomi Fujisaki; Shunji Hattori; Nobuo Sugiura; Koji Kimata; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

2.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

Authors:  Jakub Tolar; In-Hyun Park; Lily Xia; Chris J Lees; Brandon Peacock; Beau Webber; Ron T McElmurry; Cindy R Eide; Paul J Orchard; Michael Kyba; Mark J Osborn; Troy C Lund; John E Wagner; George Q Daley; Bruce R Blazar
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

3.  Decellularized ear tissues as scaffolds for stem cell differentiation.

Authors:  Peter A Santi; Shane B Johnson
Journal:  J Assoc Res Otolaryngol       Date:  2012-10-20

Review 4.  Fractones: extracellular matrix niche controlling stem cell fate and growth factor activity in the brain in health and disease.

Authors:  Frederic Mercier
Journal:  Cell Mol Life Sci       Date:  2016-07-30       Impact factor: 9.261

5.  Embryonic Stem Cell Engineering with a Glycomimetic FGF2/BMP4 Co-Receptor Drives Mesodermal Differentiation in a Three-Dimensional Culture.

Authors:  Matthew R Naticchia; Logan K Laubach; Ember M Tota; Taryn M Lucas; Mia L Huang; Kamil Godula
Journal:  ACS Chem Biol       Date:  2018-09-14       Impact factor: 5.100

6.  Enhanced control of in vivo bone formation with surface functionalized alginate microbeads incorporating heparin and human bone morphogenetic protein-2.

Authors:  Sunny Akogwu Abbah; Jing Liu; James Cho Hong Goh; Hee-Kit Wong
Journal:  Tissue Eng Part A       Date:  2012-11-07       Impact factor: 3.845

7.  A microparticle approach to morphogen delivery within pluripotent stem cell aggregates.

Authors:  Andrés M Bratt-Leal; Anh H Nguyen; Katy A Hammersmith; Ankur Singh; Todd C McDevitt
Journal:  Biomaterials       Date:  2013-07-01       Impact factor: 12.479

Review 8.  Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.

Authors:  Derbis Campos; Madelyn Monaga
Journal:  Metab Brain Dis       Date:  2012-04-14       Impact factor: 3.584

Review 9.  Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis?

Authors:  M Reza Sadaie
Journal:  Ther Adv Drug Saf       Date:  2011-12

10.  Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity.

Authors:  Jelena Brkljacic; Martina Pauk; Igor Erjavec; Antonio Cipcic; Lovorka Grgurevic; Renata Zadro; Gareth J Inman; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2013-01-10       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.